Lexie B3 vs MDHearing Volt

The Lexie B3 is a mid-priced OTC hearing aid available at $999 that achieves an A grade with a SoundScore of 4.7/5 in our lab testing, ranking #1 among 65 OTC hearing aid devices tested. This behind-the-ear style device delivers category-leading performance across multiple metrics. Speech clarity is a standout strength. In our lab testing, the Lexie B3 scores an excellent 4.5/5 for speech in quiet, measuring 1.73 points above the OTC category average. Speech in noise performance scores 2.5/5—above the category average by 1.02 points, though only mixed in absolute terms at 2.5/5. This pattern reflects the broader challenge OTC devices face in noisy environments while still positioning the B3 as a top performer relative to its category. Music streaming quality is solid at 3.3/5, outperforming the category average by 1.38 points. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above average. Feedback handling is excellent at 4.6/5, essentially matching the already-strong category average. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance without prescription hearing aid costs. Those who prioritize speech clarity in quieter settings will find particular value here. Budget-conscious shoppers may want to consider alternatives like the RxEars Rxi, which offers strong performance at a lower price point.

The MDHearing Volt is a budget-priced prescription hearing aid released in 2020, earning a B grade with a SoundScore of 3.0/5 in our lab testing. At $397, it sits in the lowest price tier for prescription devices, ranking #34 of 39 in its category. In our testing, the Volt showed a mixed performance profile with one standout strength: feedback handling scored an excellent 5.0/5, which is 0.28 points above the category average. This means users can expect minimal whistling or squealing during typical wear. However, speech performance was limited, with speech in quiet scoring 1.8/5 (1.65 points below average) and speech in noise at 1.0/5 (1.11 points below average). Own voice comfort was mixed at 2.6/5, roughly matching the category average. Music streaming capability was not functional in our testing, scoring 0.0/5—a significant limitation for users who want to stream audio from their phone. This is 2.76 points below the prescription hearing aid category average. The Volt may appeal to budget-conscious consumers who prioritize basic amplification and feedback-free wear over advanced speech enhancement or streaming features. Those seeking stronger speech performance in the same price range may want to consider alternatives like the RxEars Rxi, which scored 4.07/5 in our testing. The Volt's rechargeable battery and behind-the-ear design offer practical convenience, but its core sound performance reflects its entry-level positioning.